INT251063

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 17
Disease Relevance 3.73
Pain Relevance 0.79

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

structural molecule activity (Cldn5) plasma membrane (Cldn5)
Anatomy Link Frequency
brain 3
endothelial cells 2
vessels 1
Cldn5 (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 5 91.08 High High
ischemia 78 84.24 Quite High
imagery 22 82.52 Quite High
Neurobehavioral 11 77.20 Quite High
metalloproteinase 89 72.56 Quite High
Eae 6 55.52 Quite High
Inflammatory mediators 5 50.36 Quite High
cva 36 39.48 Quite Low
Central nervous system 21 30.76 Quite Low
Inflammation 6 26.88 Quite Low
Disease Link Frequency Relevance Heat
Coronary Artery Disease 36 99.80 Very High Very High Very High
Body Weight 22 99.50 Very High Very High Very High
Injury 42 97.98 Very High Very High Very High
Cerebral Edema 60 97.38 Very High Very High Very High
Repression 6 95.76 Very High Very High Very High
Apoptosis 24 94.24 High High
Death 6 85.68 High High
Cv Unclassified Under Development 18 84.24 Quite High
Brain Hemorrhage 54 83.92 Quite High
Infection 18 81.68 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Cldn5 expression and localization was not changed between Cre+ and control vessels (Fig.
Gene_expression (expression) of Cldn5 in vessels
1) Confidence 0.59 Published 2008 Journal The Journal of Cell Biology Section Body Doc Link PMC2575783 Disease Relevance 0 Pain Relevance 0
-cat in vivo is required to maintain high levels of Cldn5 expression in brain microvasculature.
Gene_expression (expression) of Cldn5 in brain
2) Confidence 0.59 Published 2008 Journal The Journal of Cell Biology Section Body Doc Link PMC2575783 Disease Relevance 0.10 Pain Relevance 0
Immunofluorescent staining with antiĀ–collagen IV, Cldn5, MECA-32/Plvap, VE-cad, ZO-1, and ?
Gene_expression (/) of Cldn5 associated with coronary artery disease
3) Confidence 0.51 Published 2008 Journal The Journal of Cell Biology Section Body Doc Link PMC2575783 Disease Relevance 0.10 Pain Relevance 0
Other junctional proteins, including Cldn5, VE-cad, ?
Gene_expression (proteins) of Cldn5 associated with coronary artery disease
4) Confidence 0.51 Published 2008 Journal The Journal of Cell Biology Section Body Doc Link PMC2575783 Disease Relevance 0.16 Pain Relevance 0
Cldn5 was consistently expressed in Cre?
Gene_expression (expressed) of Cldn5
5) Confidence 0.46 Published 2008 Journal The Journal of Cell Biology Section Body Doc Link PMC2575783 Disease Relevance 0.08 Pain Relevance 0
-cat signaling, whereas Cldn5, although affected in vivo by the loss of ?
Gene_expression (whereas) of Cldn5
6) Confidence 0.45 Published 2008 Journal The Journal of Cell Biology Section Body Doc Link PMC2575783 Disease Relevance 0.23 Pain Relevance 0
To characterize changes in the tight junction, we also evaluated the expression of claudin-5 with Western blotting.
Gene_expression (expression) of claudin-5
7) Confidence 0.31 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997776 Disease Relevance 0.31 Pain Relevance 0.03
In contrast, combination therapy with tPA plus cilostazol at 6 h significantly prevented a decrease in claudin-5 expression (Fig. 5G).


Gene_expression (expression) of claudin-5
8) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997776 Disease Relevance 0.23 Pain Relevance 0
Combination therapy with tPA plus cilostazol prevented development of hemorrhagic transformation, reduced brain edema, prevented endothelial injury via reduction MMP-9 activity, and prevented the blood-brain barrier opening by inhibiting decreased claudin-5 expression.
Gene_expression (expression) of claudin-5 in brain associated with injury and cerebral edema
9) Confidence 0.24 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2997776 Disease Relevance 0.43 Pain Relevance 0.11
Cilostazol increases intracellular cAMP content accordingly and activates protein kinase A (PKA) and PI3K/Akt signaling [29]. cAMP analogs enhance the barrier function of tight junctions in brain capillary endothelial cells [30]. cAMP-dependent induction of claudin-5 expression could be involved in the promotion of tight-junction function in endothelial cells [31].
Gene_expression (expression) of claudin-5 in endothelial cells
10) Confidence 0.21 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997776 Disease Relevance 0.25 Pain Relevance 0.08
Cilostazol prevented a decrease in claudin-5 expression.
Gene_expression (expression) of claudin-5
11) Confidence 0.21 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997776 Disease Relevance 0.58 Pain Relevance 0.21
Our results showed that the expression of claudin-5 was altered by tPA, which results in the disruption of the barrier permeability of neural vascular endothelial cells, and whose disruption was prevented by cilostazol.
Gene_expression (expression) of claudin-5 in endothelial cells
12) Confidence 0.21 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997776 Disease Relevance 0.45 Pain Relevance 0.24
Because PCB exposure does not alter mRNA levels of genes encoding for TJ proteins (Eum et al. 2008), our studies focused on the effects of PCBs on protein expression of claudin-5, occludin, and ZO-1.
Gene_expression (expression) of claudin-5
13) Confidence 0.17 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2854723 Disease Relevance 0 Pain Relevance 0
Exposure to PCB118 and PCB153 modulated expressional levels of claudin-5 and ZO-1, whereas PCB126 appeared to primarily influence the coassociation of occludin and ZO-1.
Gene_expression (levels) of claudin-5
14) Confidence 0.17 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2854723 Disease Relevance 0.17 Pain Relevance 0.07
Forty-eight hours after administration of PCB118 or PCB153, we observed a significant decrease in the expression of claudin-5 compared with the vehicle control group.
Gene_expression (expression) of claudin-5
15) Confidence 0.15 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2854723 Disease Relevance 0 Pain Relevance 0
mol/kg body weight) differentially altered expression of the TJ proteins claudin-5, occludin, and zonula occludens-1 in brain capillaries.
Gene_expression (expression) of claudin-5 in brain associated with body weight
16) Confidence 0.13 Published 2010 Journal Environ Health Perspect Section Abstract Doc Link PMC2854723 Disease Relevance 0.66 Pain Relevance 0.04
The changes in claudin-5 levels in PCB126-treated animals were not significant, despite demonstrating a strong trend toward a decrease.
Gene_expression (levels) of claudin-5
17) Confidence 0.13 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2854723 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox